COMPANIESAARKISH PHARMACEUTICALS NJ, INC.
✓ Verified H1B Sponsor

AARKISH PHARMACEUTICALS NJ, INC.

Fairfield, NJEIN 825351886
TRUST SCORE
85.7
High Trust
6
FY2024 H1B Approvals
6
All-time Approvals
85.7
Trust Score / 100

TOP SPONSORED JOB CATEGORIES

Regulatory Affairs SpecialistsChemistsSales Representatives, Wholesale and Manufacturing, Technical and Scientific Products

RECENT H1B FILINGS

JOB TITLELOCATIONWAGEDATE
Regulatory Affairs SpecialistsFairfield, NJ$60,600Oct 2025
ChemistsFairfield, NJ$63,200Oct 2025
ChemistsFairfield, NJ$63,200Oct 2025
Regulatory Affairs SpecialistsFairfield, NJ$60,600Oct 2025
Sales Representatives, Wholesale and Manufacturing, Technical and Scientific ProductsFairfield, NJ$75,000Oct 2025
Regulatory Affairs SpecialistsFairfield, NJ$78,000Oct 2024
Regulatory Affairs SpecialistsFairfield, NJ$78,000Oct 2024

SHOWING 50 MOST RECENT · SOURCE: DOL LCA PUBLIC DATA FY2024 · EIN 825351886

FREQUENTLY ASKED QUESTIONS

Does AARKISH PHARMACEUTICALS NJ, INC. sponsor H1B visas?

Yes. AARKISH PHARMACEUTICALS NJ, INC. has an active H1B sponsorship history with 6 total approved LCA filings on record, including 6 approvals in FY2024. Data sourced from US Department of Labor public disclosure files.

How many H1B visas has AARKISH PHARMACEUTICALS NJ, INC. sponsored?

According to DOL LCA data, AARKISH PHARMACEUTICALS NJ, INC. has 6 all-time H1B approvals and 6 approvals in fiscal year 2024.

What types of roles does AARKISH PHARMACEUTICALS NJ, INC. sponsor H1B for?

AARKISH PHARMACEUTICALS NJ, INC. most commonly sponsors H1B visas for: Regulatory Affairs Specialists, Chemists, Sales Representatives, Wholesale and Manufacturing, Technical and Scientific Products. This is based on their DOL Labor Condition Application filing history.

Is AARKISH PHARMACEUTICALS NJ, INC. a reliable H1B sponsor?

AARKISH PHARMACEUTICALS NJ, INC. has a Trust Score of 85.7/100 on KEEL, calculated from total approval volume, recency of filings, and approval consistency based on DOL LCA data.

DATA SOURCE: US DEPT. OF LABOR · LCA PUBLIC DISCLOSURE FY2023–FY2024